TAS::75 0849::TAS

塔斯马尼亚州::75 0849::塔斯马尼亚州

• 批准号: 8163697
• 负责人: DENNIS M. DEAPEN
• 金额: $ 15.05万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8163697
• 关键词: TAS; 75; 0849

The Los Angeles SEER Residual Tissue Repository (RTR) will produce a tissue-based resource for research purposes consisting of cancer tumor specimens from HIV/AIDS patients and similar cancer tumor specimens from patients without HIV/AIDS in a multi-tumor block. HIV/AIDS patients will be identified from the previous Los Angeles County Department of Health Services HIV/AIDS ¿USC Cancer Surveillance Program database linkage, and also from a new linkage proposed for this coming year. The objective is to develop a collection of biospecimens 970 cancer patients. The following types of cancers specimens will be targeted for cases with HIV/AIDS: melanoma (n-30), Hodgkin lymphoma (n=30), non-Hodgkin lymphoma (n=200), lung cancer (n=50), cervical cancer (n=40), and anal cancer (n=40). Cancer patients unaffected by HIV/AIDS but with similar cancers will also be selected for comparison with a 2:1 matching ratio with the exception of non-Hodgkin lymphoma cancers will also be selected for comparison with a 1:1 matching ratio,. Specimens will be obtained from the Los Angeles SEER Residual Tissue Repository to the extent possible (Phase 1). Additional specimens will be obtained directly from hospitals after obtaining consent from patients (Phase 2). Multi-tumor and/or tissue microarrays containing cores or samples of the tumor specimen will be prepared and linked to deidentified SEER data (Phase III). This research resource will made available to NCI as a research resource to study differences in tumor marker profiles between HIV/AIDS positive and negative cancer patients. The NCI AIDS Tissue Resource will be the home of record for the completed resource. For confidentiality purposes, the Los Angeles SEER registry will maintain files that link specimen numbers to identifiers. An advisory board that includes Los Angeles SEER RTR and NCI personnel will co-review applications to use the resulting biospecimens collection.

洛杉矶SEER残留组织储存库(RTR)将为研究目的制作一个基于组织的资源，其中包括来自艾滋病毒/艾滋病患者的癌症肿瘤样本，以及来自多肿瘤区块中非艾滋病毒/艾滋病患者的类似癌症肿瘤样本。艾滋病毒/艾滋病患者将从以前洛杉矶县卫生服务部艾滋病毒/艾滋病？南加州大学癌症监测计划数据库链接中确定，也将从明年拟议的新链接中确定。其目标是开发一组970名癌症患者的生物样本。以下类型的癌症样本将用于艾滋病毒/艾滋病病例：黑色素瘤(n-30)、霍奇金淋巴瘤(n=30)、非霍奇金淋巴瘤(n=200)、肺癌(n=50)、宫颈癌(n=40)和肛门癌(n=40)。未受爱滋病病毒/爱滋病影响但癌症相似的癌症病人亦会被选作2：1配对比率比较，但非霍奇金淋巴瘤癌症除外，亦会被选作1：1配对比例比较。标本将尽可能从洛杉矶SEER残留组织储存库获得(第一阶段)。在征得患者同意后，将直接从医院获得更多样本(第二阶段)。将准备包含肿瘤标本核心或样本的多个肿瘤和/或组织微阵列，并将其与已确定的SEER数据联系起来(第三阶段)。这项研究资源将作为研究资源提供给NCI，以研究艾滋病毒/艾滋病阳性和阴性癌症患者之间肿瘤标志物特征的差异。NCI艾滋病组织资源将成为完整资源的记录之家。出于保密目的，洛杉矶SEER登记处将维护将标本编号与识别符联系起来的文件。一个由洛杉矶SEER、RTR和NCI人员组成的顾问委员会将共同审查使用由此产生的生物标本收集的申请。